A Trial of Targeted Therapies for Patients With Slow-Flow or Fast-Flow Vascular Malformations
Status:
RECRUITING
Trial end date:
2026-12-01
Target enrollment:
Participant gender:
Summary
Recent studies have demonstrated that growth of vascular malformations can be driven by genetic variants in one of 2 signalling pathways. Targeted drugs specific to these pathways have been developed and shown to be effective in treating cancer. This study will describe the effectiveness of (i) 48 weeks of alpelisib therapy for participants with slow-flow vascular malformations and a gene mutation in one of these signalling pathways (module 1) and (ii) 48 weeks of mirdametinib therapy for participants with fast-flow vascular malformations and a gene mutations in the other signalling pathway (module 2).
Phase:
PHASE2
Details
Lead Sponsor:
Murdoch Childrens Research Institute
Collaborators:
Peter MacCallum Cancer Centre, Australia Royal Children's Hospital